BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1064 related articles for article (PubMed ID: 34781748)

  • 1. Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.
    Ruiz-Rodriguez P; Francés-Gómez C; Chiner-Oms Á; López MG; Jiménez-Serrano S; Cancino-Muñoz I; Ruiz-Hueso P; Torres-Puente M; Bracho MA; D'Auria G; Martinez-Priego L; Guerreiro M; Montero-Alonso M; Gómez MD; Piñana JL; ; González-Candelas F; Comas I; Marina A; Geller R; Coscolla M
    mBio; 2021 Dec; 12(6):e0231521. PubMed ID: 34781748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 evolution during treatment of chronic infection.
    Kemp SA; Collier DA; Datir RP; Ferreira IATM; Gayed S; Jahun A; Hosmillo M; Rees-Spear C; Mlcochova P; Lumb IU; Roberts DJ; Chandra A; Temperton N; ; ; Sharrocks K; Blane E; Modis Y; Leigh KE; Briggs JAG; van Gils MJ; Smith KGC; Bradley JR; Smith C; Doffinger R; Ceron-Gutierrez L; Barcenas-Morales G; Pollock DD; Goldstein RA; Smielewska A; Skittrall JP; Gouliouris T; Goodfellow IG; Gkrania-Klotsas E; Illingworth CJR; McCoy LE; Gupta RK
    Nature; 2021 Apr; 592(7853):277-282. PubMed ID: 33545711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape.
    Schmidt F; Weisblum Y; Rutkowska M; Poston D; DaSilva J; Zhang F; Bednarski E; Cho A; Schaefer-Babajew DJ; Gaebler C; Caskey M; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Nature; 2021 Dec; 600(7889):512-516. PubMed ID: 34544114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential.
    Kubik S; Arrigo N; Bonet J; Xu Z
    Viruses; 2021 Oct; 13(11):. PubMed ID: 34834921
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural and antigenic variations in the spike protein of emerging SARS-CoV-2 variants.
    Mittal A; Khattri A; Verma V
    PLoS Pathog; 2022 Feb; 18(2):e1010260. PubMed ID: 35176090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SARS-CoV-2 worldwide transmission based on evolutionary dynamics and specific viral mutations in the spike protein.
    Liu J; Chen X; Liu Y; Lin J; Shen J; Zhang H; Yin J; Pu R; Ding Y; Cao G
    Infect Dis Poverty; 2021 Aug; 10(1):112. PubMed ID: 34419160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.
    Müller K; Girl P; Giebl A; Gruetzner S; Antwerpen M; Khatamzas E; Wölfel R; von Buttlar H
    Virus Genes; 2021 Dec; 57(6):502-509. PubMed ID: 34608598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.
    Yi C; Sun X; Lin Y; Gu C; Ding L; Lu X; Yang Z; Zhang Y; Ma L; Gu W; Qu A; Zhou X; Li X; Xu J; Ling Z; Xie Y; Lu H; Sun B
    Genome Med; 2021 Oct; 13(1):164. PubMed ID: 34649620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a High-Frequency Intrahost SARS-CoV-2 Spike Variant with Enhanced Cytopathic and Fusogenic Effects.
    Rocheleau L; Laroche G; Fu K; Stewart CM; Mohamud AO; Côté M; Giguère PM; Langlois MA; Pelchat M
    mBio; 2021 Jun; 12(3):e0078821. PubMed ID: 34182784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity.
    Kuzmina A; Wattad S; Engel S; Rosenberg E; Taube R
    Viruses; 2022 Apr; 14(4):. PubMed ID: 35458533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Founder Effect Led Early SARS-CoV-2 Transmission in Spain.
    Díez-Fuertes F; Iglesias-Caballero M; García-Pérez J; Monzón S; Jiménez P; Varona S; Cuesta I; Zaballos Á; Jiménez M; Checa L; Pozo F; Pérez-Olmeda M; Thomson MM; Alcamí J; Casas I
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33127745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic Variants.
    Sun F; Wang X; Tan S; Dan Y; Lu Y; Zhang J; Xu J; Tan Z; Xiang X; Zhou Y; He W; Wan X; Zhang W; Chen Y; Tan W; Deng G
    Microbiol Spectr; 2021 Sep; 9(1):e0026121. PubMed ID: 34346744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intra-host non-synonymous diversity at a neutralizing antibody epitope of SARS-CoV-2 spike protein N-terminal domain.
    Ip JD; Kok KH; Chan WM; Chu AW; Wu WL; Yip CC; To WK; Tsang OT; Leung WS; Chik TS; Chan KH; Hung IF; Yuen KY; To KK
    Clin Microbiol Infect; 2021 Sep; 27(9):1350.e1-1350.e5. PubMed ID: 33144203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021.
    Bui NN; Lin YT; Huang SH; Lin CW
    Infect Genet Evol; 2022 Jan; 97():105164. PubMed ID: 34848355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.
    Syed AM; Ciling A; Taha TY; Chen IP; Khalid MM; Sreekumar B; Chen PY; Kumar GR; Suryawanshi R; Silva I; Milbes B; Kojima N; Hess V; Shacreaw M; Lopez L; Brobeck M; Turner F; Spraggon L; Tabata T; Ott M; Doudna JA
    Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2200592119. PubMed ID: 35858386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Previous Infection Combined with Vaccination Produces Neutralizing Antibodies with Potency against SARS-CoV-2 Variants.
    Ibarrondo FJ; Hofmann C; Ali A; Ayoub P; Kohn DB; Yang OO
    mBio; 2021 Dec; 12(6):e0265621. PubMed ID: 34872349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021.
    Alkhatib M; Svicher V; Salpini R; Ambrosio FA; Bellocchi MC; Carioti L; Piermatteo L; Scutari R; Costa G; Artese A; Alcaro S; Shafer R; Ceccherini-Silberstein F
    Microbiol Spectr; 2021 Dec; 9(3):e0109621. PubMed ID: 34787497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 54.